Skip Navigation



JAC Advance Access published online on June 20, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl245
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/455    most recent
dkl245v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carey, B. E.
Right arrow Articles by Dancer, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carey, B. E.
Right arrow Articles by Dancer, S. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received March 20, 2006
Revised May 15, 2006
Accepted May 22, 2006

Brief report

Reversing methicillin resistance in MRSA using a bacterial transforming agent

Bryan E. Carey 1 and Stephanie J. Dancer 1 *

1 Department of Microbiology, Southern General Hospital, Glasgow G51 4TF, Scotland, UK

* To whom correspondence should be addressed.
Stephanie J. Dancer, E-mail: Stephanie.Dancer{at}sgh.scot.nhs.uk


  Abstract

Background: Antimicrobial resistance in staphylococci remains a significant problem in the clinical management of infections. New therapeutic entities are required for the prophylaxis and treatment of staphylococcal infection including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Potential candidates include bacterial transforming agents (BTAs), compounds that can potentiate the activity of cell-wall-active antimicrobials by hypersensitizing the bacterial cell wall to the bactericidal effects of these drugs. BTAs have been found to inhibit MRSA in vitro when administered in combination with established antibiotics.

Objectives: To examine the antimicrobial potential of a known BTA (BTA 19976a) on strains of MRSA in vitro.

Methods: Etest and time-kill methodologies were employed to assess the inhibitory potential of BTA at 10% w/v on strains of E-MRSA-3, E-MRSA-15 and E-MRSA-16.

Results: Etests demonstrated a reduction in the oxacillin MIC for E-MRSA-3, E-MRSA-15 and the NCTC 12493 reference strain of MRSA when exposed to BTA at 10% w/v. Time-kill assays similarly demonstrated a reduction in viable counts for organisms exposed to methicillin at 40 mg/L + BTA at 10% w/v, compared with methicillin alone, an effect which varied in cidality, pattern of killing and regrowth between strains.

Conclusions: The antimicrobial effects of this BTA on MRSA are encouraging and warrant further investigation with large numbers of different epidemic strains and a comprehensive PK/PD evaluation. This could lead to new therapeutic entities for the prophylaxis and treatment of staphylococcal infections.

Keywords: anti-infective development; drug susceptibility testing; {beta}-lactams; cell wall; hypersensitizing agent.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.